Text Size

Value of Fecal Calprotectin

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2007 by Indiana University.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Indiana University
ClinicalTrials.gov Identifier:
NCT00577928
First received: December 19, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted
  Purpose

For the main goal - the accuracy of calprotectin for the diagnosis of IBD - calprotectin levels will be compared between patients with and without a diagnosis of IBD and the sensitivity, specificity and accuracy will be determined. For the secondary aim - the correlation between calprotectin levels and disease activity - in patients with IBD selected from this cohort, we will determine the association between calprotectin levels and clinical IBD score, serological markers (WBC, Hgb, Platelets, ESR, CRP, Albumin), endoscopic (disease score, pathological activity) and radiological features (bowel wall thickening, enhancement, edema, mesenteric inflammation).


Condition
Calprotectin
Inflammatory Bowel Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Correlation of Fecal Calprotectin Level With the Clinical, Endoscopic, Histologic and Radiologic Activity in Inflammatory Bowel diseaseThe Value of Fecal Calprotectin for the Diagnosis and Assessment of Inflammatory Bowel Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Indiana University:

Estimated Enrollment: 100
Study Start Date: April 2006
Estimated Study Completion Date: December 2007

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All patients who had calprotectin assays as part of their evaluations for lower gastrointestinal symptoms in the Division of Gastroenterology at IU within the last 12 months will be considered eligible for the study.

Criteria

Inclusion Criteria:

  • Calprotectin assay at IU in last 12 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00577928

Locations
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Michael Chiorean, M.D. Indiana University
  More Information

No publications provided

Responsible Party: Michael Chiorean, M.D., Indiana University
ClinicalTrials.gov Identifier: NCT00577928     History of Changes
Other Study ID Numbers: 060362, IRB# 0603-62
Study First Received: December 19, 2007
Last Updated: December 19, 2007
Health Authority: United States: Institution Review Board

Additional relevant MeSH terms:
Inflammatory Bowel Diseases
Intestinal Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 21, 2013